title: Malignant small bowel neoplasms: histopathologic determinants of recurrence and survival.
abstract: BACKGROUND
  Small bowel neoplasms account for only a small percentage of gastrointestinal tumors, but their prognosis is one of the worst.
  
  
  OBJECTIVE
  This study examines the histopathology, treatment, recurrence, and overall survival of a group of patients with primary small bowel tumors.
  
  
  METHODS
  From 1970 to 1991, a retrospective review identified 73 patients with primary small bowel tumors. Four histologic groups were identified: 1) group 1, adenocarcinoma, 29 patients; group 2, lymphoma, 18 patients; group 3, sarcoma, 8 patients; and group 4, carcinoid, 18 patients. There were 44 men and 29 women. The median age was 57 years (range, 26 to 90). Median follow-up was 15 months. Survival analysis was by the Mantel-Cox and Breslow methods.
  
  
  RESULTS
  The most common, by type, was group 1, duodenum; group 2, jejunum; group 3, jejunum; and group 4, ileum. The preoperative diagnosis was made in only 14 patients. The median survival for adenocarcinomas and lymphomas was 13 months, 18 months for sarcomas, and 36 months for carcinoids. Curative resection could be achieved in 48 (65%) of 73 patients, and the median survival was significantly longer for this group (26 months vs. 11 months, p < 0.05). Of the 48 curative resections, 20 patients (42%) recurred: group 1, 8/19 (42%); group 2, 4/12 (33%); group 3, 4/13 (31%); group 4, 4/4 (100%). The median time to recurrence was 17 months, and the median survival after recurrence was 20 months. Adjuvant chemotherapy-radiation therapy did not alter survival in any group.
  
  
  CONCLUSIONS
  The preoperative diagnosis of small bowel tumors rarely is made because symptoms are vague and nonspecific. Surgical resection for cure results in improved survival. Recurrence is common and survival after recurrence is poor. Other treatment methods have no role in the management of these patients.
authors.affiliation: Department of Surgery, Mount Sinai Medical Center, New York, New York 10029, USA.
authors.forename: J D
authors.initials: JD
authors.lastname: Cunningham
authors.forename: R
authors.initials: R
authors.lastname: Aleali
authors.forename: M
authors.initials: M
authors.lastname: Aleali
authors.forename: S T
authors.initials: ST
authors.lastname: Brower
authors.forename: A H
authors.initials: AH
authors.lastname: Aufses
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002276:Carcinoid Tumor / Q000401:mortality / Q000473:pathology / Q000628:therapy; D004379:Duodenal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D005260:Female; D006801:Humans; D007078:Ileal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D007580:Jejunal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008223:Lymphoma / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D012189:Retrospective Studies; D012509:Sarcoma / Q000401:mortality / Q000473:pathology / Q000628:therapy; D015996:Survival Rate